(Q84190034)
Statements
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07 (English)
Olivier Michielin
Holger Moch
Reinhard Dummer
Peter Schraml
Adriana von Teichman
Daniela Mihic-Probst
Mathew Simcock
Adrian Ochsenbein
Bettina Seifert
Marc Schläppi
1 reference